{"product_id":"biopharmaceutical-informatics-learning-to-discover-developable-biotherapeutics-paperback","title":"Biopharmaceutical Informatics: Learning to Discover Developable Biotherapeutics - Paperback","description":"\u003cdiv\u003e\u003cp style=\"text-align: right;\"\u003e\u003ca href=\"https:\/\/reportcopyrightinfringement.com\/\" target=\"_blank\" rel=\"nofollow\"\u003e\u003cb\u003eReport copyright infringement\u003c\/b\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/div\u003e\u003cp\u003eby \u003cb\u003eSandeep Kumar\u003c\/b\u003e (Editor), \u003cb\u003eAndrew Nixon\u003c\/b\u003e (Editor)\u003c\/p\u003e\u003cp\u003eThis book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics.\u003c\/p\u003e\u003ch3\u003eAuthor Biography\u003c\/h3\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. Sandeep Kumar \u003c\/b\u003eis currently a Distinguished Fellow (Executive Director) at the department of Computational Science in Moderna Therapeutics, Cambridge, MA where he leads Molecular Design and Modeling team. Sandeep Kumar holds a Ph.D. in Computational Biophysics and has over 25 years of experience researching protein structure - Function relationships. Sandeep Kumar has so far contributed towards more than 100 research articles, reviews, book chapters, and has previously edited a book entitled \"Developability of Biotherapeutics: Computational Approaches\". Sandeep has been contributing towards discovery and development of numerous monoclonal antibodies, antibody drug conjugates, bispecific and multi-specific modalities, as well as vaccines. Based on the insights gained from these experiences, Sandeep has been advocating for Biopharmaceutical Informatics, a strategic vision dedicated to synergistic use of computation and experimentation towards a cost effective and more efficient discovery and development of Biotherapeutics. More recently, he is promoting the concept of DAbI (Discovery of Antibodies in silico) where he sees an opportunity for generative AI to not only accelerate biopharmaceutical drug design but also to expand the antigen space druggable by antibody-based biotherapeutics.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. Andrew Nixon \u003c\/b\u003eis currently Vice President, Biotherapeutics Molecule Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Andy earned his Ph.D. in Physical Biochemistry from the University of London for studies completed at the MRC's National Institute for Medical Research. Andy has over 20 years of experience in biologic drug discovery and has contributed to over 100 antibody discovery programs resulting in numerous clinical candidates and approved biologics including TAKHZYRO, a fully human antibody inhibitor of plasma kallikrein.\u003c\/p\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eNumber of Pages:\u003c\/strong\u003e 368\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eDimensions:\u003c\/strong\u003e 0.8 x 9.21 x 6.14 IN\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eIllustrated:\u003c\/strong\u003e Yes\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003ePublication Date:\u003c\/strong\u003e May 21, 2026\u003c\/div\u003e\n            ","brand":"BooksCloud","offers":[{"title":"Default Title","offer_id":48532423442653,"sku":"9781032291680","price":143.83,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0811\/9867\/8237\/files\/HCaaU1kHCN9781032291680.webp?v=1788975478","url":"https:\/\/handfulofbooks.com\/products\/biopharmaceutical-informatics-learning-to-discover-developable-biotherapeutics-paperback","provider":"Handful of Books","version":"1.0","type":"link"}